About Respira Therapeutics
Respira Therapeutics is a company based in Albuquerque (United States) founded in 2010 was acquired by Gossamer Bio in September 2025. Respira Therapeutics has raised $9.11 million across 3 funding rounds from investors including Gossamer Bio, HHS and Sun Mountain Capital. The company has 6 employees. Respira Therapeutics offers products and services including RT234-PAH. Respira Therapeutics operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Albuquerque, United States
- Employees 6
- SectorsHealthcare
- Email••••••••
- Website respiratherapeutics.com
- Social LinkedIn X
- Acquired by Gossamer Bio (Sep 2025)
- Legal Name Respira Therapeutics, Inc.
- Total Equity Funding$9.11M (USD)
in 3 rounds
- Latest Funding Round$224.94K (USD), Grant
Aug 2019
- InvestorsGossamer Bio
& 3 more
- Employee Count6
- Acquired byGossamer Bio
(Sep 2025)
Products & Services of Respira Therapeutics
Respira Therapeutics offers a comprehensive portfolio of products and services, including RT234-PAH.
Inhaled treatment for pulmonary arterial hypertension to relieve breathlessness.
Funding Insights of Respira Therapeutics
Respira Therapeutics has successfully raised a total of $9.11M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $224.94 thousand completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.11M
- Total Rounds 3
- Last Round Grant — $224,939
- Investors Count 3
All 3 funding rounds of Respira Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2019 | $224,939 | Grant | – | – | |
| Apr 2017 | $9.11M | Series A | – | – | – |
| Dec 2013 | – | Series A | – | – |
4 investors in total: 4 institutional.
Investors in Respira Therapeutics
Respira Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Gossamer Bio, HHS and Sun Mountain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on multiple sectors | 2006 | sunmountaincapital.com | Santa Fe, United States | |
- | – | cottonwood.vc | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer | 2017 | gossamerbio.com | San Diego, United States |
Investor details for Respira Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Respira Therapeutics
2 people are tracked at Respira Therapeutics (1 in board & advisors, 1 in team); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
Mike Dybbs | Chairman | Board & advisors |
William Fairey | Chairman | Team |
Complete people profiles for Respira Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Respira Therapeutics
4 dated milestones of Respira Therapeutics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Respira Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $225K.
- Exit Acquired by Gossamer Bio.
Competitors of Respira Therapeutics
Respira Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Respira Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Respira Therapeutics
The website of Respira Therapeutics (respiratherapeutics.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 79.7% vs previous month
Latest news on Respira Therapeutics
Complete news archive for Respira Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Respira Therapeutics
10 companies that operate in the same segment as Respira Therapeutics (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Respira Therapeutics
Respira Therapeutics was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Respira Therapeutics is headquartered in Albuquerque, United States. It is registered at Albuquerque, New Mexico, United States.
Respira Therapeutics is a funded company, having raised a total of $9.11M across 3 funding rounds to date.
Respira Therapeutics has 6 employees.
Respira is a product development-stage company focused on pulmonary delivery of therapeutics for respiratory diseases. It is applying its patented, high-efficiency AOS Dry Powder Inhaler (DPI) technologies to uniquely enable the highly targeted lung delivery of drugs to treat pulmonary diseases. building an internal pipeline and also seeking partnerships for the use of our DPI products with proprietary drugs. Its lead product is RT234AOS-DPI, a combination of RT234 (a proprietary inhaled formulation of an off-patent drug) and its patented AOS-DPI to treat Pulmonary Arterial Hypertension.
Respira Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Respira Therapeutics offers RT234-PAH.
Respira Therapeutics has 4 investors. Key investors include Gossamer Bio, HHS, Sun Mountain Capital, and Cottonwood Technology Fund.
Respira Therapeutics operates through Respira Therapeutics, Inc..
Yes. Respira Therapeutics was acquired by Gossamer Bio in September 2025.